120 related articles for article (PubMed ID: 10605752)
1. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A.
Zhang WW; Josephs SF; Zhou J; Fang X; Alemany R; Balagué C; Dai Y; Ayares D; Prokopenko E; Lou YC; Sethi E; Hubert-Leslie D; Kennedy M; Ruiz L; Rockow-Magnone S
Thromb Haemost; 1999 Aug; 82(2):562-71. PubMed ID: 10605752
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
4. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.
Connelly S; Andrews JL; Gallo-Penn AM; Tagliavacca L; Kaufman RJ; Kaleko M
Thromb Haemost; 1999 Feb; 81(2):234-9. PubMed ID: 10063998
[TBL] [Abstract][Full Text] [Related]
6. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.
Bristol JA; Shirley P; Idamakanti N; Kaleko M; Connelly S
Mol Ther; 2000 Sep; 2(3):223-32. PubMed ID: 10985953
[TBL] [Abstract][Full Text] [Related]
7. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
8. Preclinical gene therapy studies for hemophilia using adenoviral vectors.
Thorrez L; VandenDriessche T; Collen D; Chuah MK
Semin Thromb Hemost; 2004 Apr; 30(2):173-83. PubMed ID: 15118929
[TBL] [Abstract][Full Text] [Related]
9. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
10. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
11. Preclinical animal models for hemophilia gene therapy: predictive value and limitations.
Rawle FE; Lillicrap D
Semin Thromb Hemost; 2004 Apr; 30(2):205-13. PubMed ID: 15118932
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for hemophilia A.
Connelly S; Kaleko M
Thromb Haemost; 1997 Jul; 78(1):31-6. PubMed ID: 9198123
[TBL] [Abstract][Full Text] [Related]
13. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
[TBL] [Abstract][Full Text] [Related]
14. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
Kikuchi J; Mimuro J; Ogata K; Tabata T; Ueda Y; Ishiwata A; Kimura K; Takano K; Madoiwa S; Mizukami H; Hanazono Y; Kume A; Hasegawa M; Ozawa K; Sakata Y
J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for hemophilia.
Chuah MK; Collen D; VandenDriessche T
J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary experimental research on gene therapy for hemophilia A].
Yin J; Wang H; Hu Y; Wang X; Qu B; Chu H; Duan B; Kang W; Qi Z; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2002 Mar; 23(3):138-42. PubMed ID: 12015067
[TBL] [Abstract][Full Text] [Related]
19. Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia.
Miller G; Steinbrecher RA; Murdock PJ; Tuddenham EG; Lee CA; Pasi KJ; Goldspink G
Gene Ther; 1995 Dec; 2(10):736-42. PubMed ID: 8750013
[TBL] [Abstract][Full Text] [Related]
20. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector.
Reddy PS; Sakhuja K; Ganesh S; Yang L; Kayda D; Brann T; Pattison S; Golightly D; Idamakanti N; Pinkstaff A; Kaloss M; Barjot C; Chamberlain JS; Kaleko M; Connelly S
Mol Ther; 2002 Jan; 5(1):63-73. PubMed ID: 11786047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
